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Abstract
Background: Pandemic influenza is said to ‘shift mortality’ to younger age groups; but also to spare a
subpopulation of the elderly population. Does one of these effects dominate? Might this have important
ramifications?
Methods: We estimated age-specific excess mortality rates for all-years for which data were available in the 20th
century for Australia, Canada, France, Japan, the UK, and the USA for people older than 44 years of age. We
modeled variation with age, and standardized estimates to allow direct comparison across age groups and
countries. Attack rate data for four pandemics were assembled.
Results: For nearly all seasons, an exponential model characterized mortality data extremely well. For seasons of
emergence and a variable number of seasons following, however, a subpopulation above a threshold age
invariably enjoyed reduced mortality. ‘Immune escape’, a stepwise increase in mortality among the oldest elderly,
was observed a number of seasons after both the A(H2N2) and A(H3N2) pandemics. The number of seasons from
emergence to escape varied by country. For the latter pandemic, mortality rates in four countries increased for
younger age groups but only in the season following that of emergence. Adaptation to both emergent viruses
was apparent as a progressive decrease in mortality rates, which, with two exceptions, was seen only in younger
age groups. Pandemic attack rate variation with age was estimated to be similar across four pandemics with very
different mortality impact.
Conclusions: In all influenza pandemics of the 20th century, emergent viruses resembled those that had circulated
previously within the lifespan of then-living people. Such individuals were relatively immune to the emergent
strain, but this immunity waned with mutation of the emergent virus. An immune subpopulation complicates and
may invalidate vaccine trials. Pandemic influenza does not ‘shift’ mortality to younger age groups; rather, the
mortality level is reset by the virulence of the emerging virus and is moderated by immunity of past experience. In
this study, we found that after immune escape, older age groups showed no further mortality reduction, despite
their being the principal target of conventional influenza vaccines. Vaccines incorporating variants of pandemic
viruses seem to provide little benefit to those previously immune. If attack rates truly are similar across pandemics,
it must be the case that immunity to the pandemic virus does not prevent infection, but only mitigates the
consequences.
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immunity
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Background
Viewed against the backdrop of social evolution, the age
distribution of the probability of death in human popu-
lations has a checkmark-like shape. The top curve in
Figure 1 characterizes a society with life expectancy at
birth of 20 years, about that for ancient Greece at the
time of Pericles (448 to 404 BC). The lowest curve
depicts the deathscape of a modern economically devel-
oped country, around 1950. The nested checkmark
shapes derive from the fact that the mortality of infants
and young children has always been greater than that of
8- to 12-year-olds. Above this age range, mortality rates
steadily increase. The most important additional feature
is that the segment of each curve for ages of around 40
years and older approximates a straight line Because the
ordinate of the graph is plotted on a logarithmic scale, a
straight line indicates that human mortality increases
about exponentially with age from young middle age
onwards. Over the approximately 2,400 years between
425 BC and 1950 AD, the death rate of 80-year-olds
decreased by approximately 50%, or approximately 2%
per century. Over the next 50 years, this death rate fell
by an additional one-third in economically developed
countries such as Canada (Figure 2). This is perhaps less
remarkable than the fall of 70 to 80% in mortality for
children from infancy to 12 years old over the same fifty
years, but is evidence of true progress in human life
extension.
Influenza-attributable or excess mortality has also been
found to be exponential with age [1,2]. Figure 3 displays
excess all-cause (AC) mortality rates (estimated using the
technique of this paper) for Canada, for a selected set of
epidemic seasons in the era of circulation of A(H2N2)
viruses in seasons dominated by H2 and B viruses. Trend
lines are plotted for these seasons. It is clear that an
exponential relationship exists, and that this relationship
is quite similar for seasons of a type. Excess AC mortality
rates in 85- to 90-year-olds are about 250 times greater
than those for 45 to 50-year-olds, whereas AC total mor-
tality rates for 85 to 90-year-olds are only about 75 times
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Figure 1 The probability of death versus age for human populations of successively longer median life expectancy (expressed as
deaths per 1000 population). Source: Department of Social Affairs. Population Branch, Age and Sex Patterns of Mortality: Model Life Tables for
Underdeveloped Countries. Population Studies, No. 22, New York, United Nations, 1955.
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larger than the rates for 45- to 50-year- olds. A charac-
teristic of exponential processes is that a proportional
change in the process occurs as a result of a fixed change
in the driver of the process, here, age. The age increase
associated with a doubling of the AC mortality rate was
7.15 years in Canada in 1999, while the doubling age
increment for influenza-attributable mortality was 5.33
years. The exponential variation with age is, therefore,
steeper for influenza-attributable mortality than for AC
mortality. Seasonal influenza, as a mortal force, is of unu-
sual consequence to the increasingly elderly population.
Two generalizations can be made from Figure 3. First,
it is clear that excess mortality was higher in seasons in
which mortality was dominated by influenza A-type
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Figure 2 The evolution of observed age-specific all-cause mortality rates, scaled per 1000 population, in Canada over the second half
of the 20th century. This evolution dovetails with the historical model of socioeconomic evolution.
Figure 3 A semi-log plot of excess all-cause mortality variation with age for epidemic seasons during the era of circulation of
influenza A(H2N2) viruses in Canada. The 1960/61 and 1964/5 seasons were dominated by B-type viruses, and the 1962/3 and 1967/8
seasons were dominated in mortality by H2N2 viruses.
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viruses. The pair of lines for H2 seasons lay wholly
above the pair for B-type seasons, and the excess mor-
tality rate was estimated to be about twice as great for
the H2 seasons for each age group. The currently circu-
lating subtypes of A-type influenza (H1, H2, and H3)
have circulated in humans only since about the middle
of the 19th century [3,4]. These viruses seem to have
crossed the species barrier from the avian reservoir, pos-
sibly through an intermediate reservoir. A-type viruses
mutate (at the nucleotide level) and evolve (at the
amino acid level) relatively rapidly. By contrast, B-type
influenza viruses have no known animal reservoir, and
mutate and evolve at about half the rate of A-type
viruses. They seem to be descended from a more
ancient ancestor, and are correspondingly better adapted
to humans. Possibly as a result, large changes with pan-
demic effect do not occur with B-type viruses and sev-
eral lineages co-circulate [5].
Second, in inter-pandemic seasons dominated by A-
type viruses, excess mortality generally declined with
time, as the population adapted to viruses that had
drifted modestly from those of earlier seasons. This
occurred significantly more frequently in younger than
in older age groups, with the result that the slopes of
lines fit to points representing excess mortality in sea-
sons dominated by the same type of virus tended to
increase with time. In addition, periods of adaptation
were necessarily interrupted by seasons in which muta-
tions produced sufficiently large changes in antigenicity
that the immunologic adaptations were abrogated in at
least a subset of the population, and re-infection
occurred, with corresponding rises in morbidity and
excess mortality. The evolutionary dynamics of the A
(H1), A(H2) and A(H3) viruses are different [4,6], so the
situation became much more complex after 1977 when
H1 viruses re-emerged. These have co-circulated since
that time along with H3 viruses. H1 viruses have diverse
lineages and weaker antigenic drift, but this was not
always the case [7]. H1 seasons are currently milder
than H3 seasons, producing only slightly higher morbid-
ity and mortality than seasons dominated by B-type
viruses.
The largest numbers of deaths associated with influ-
enza infection occurred in the years associated with the
emergence of influenza viruses that were novel to most
of the world’s population, and also in the seasons imme-
diately following this emergence [8]. The phrase ‘pan-
demic age shift’ is usually invoked to describe the
observed increase in mortality among younger people in
the first season of emergence of a novel influenza virus
[9]. In the recent 2009 H1N1 pandemic, both cases and
deaths exhibited a clear predilection for younger age
groups [10-13]. The mini-pandemic of 1977 produced
substantial morbidity only in those under the age of 26
[14], and the infamous ‘W-shaped’ mortality curve of
the 1918 pandemic reflected the unusually high mortal-
ity rate for 18- to 44-year-olds [15]. This raises several
questions: Are younger immune systems more suscepti-
ble to and more severely affected by novel viruses? Or is
mortality in pandemic seasons merely reset to the viru-
lence level of the emerging virus, except among those
immune by virtue of previous exposure, most of whom
will be older? Is it possible to distinguish between these
hypotheses using the data on pandemic mortality and
that in the seasons immediately preceding and following
emergence? Increasing our understanding of the epide-
miological patterns of mortality during influenza pan-
demics compared with inter-pandemic periods in
different parts of the world could lead to improved
influenza control strategies.
In the present study, we generated, analyzed and inte-
grated data on the mortality impact of influenza on the
healthcare systems of six economically developed coun-
tries in and near the pandemics of the last fifty years of
the 20th century.
Methods
The data for this study were obtained from the national
health systems of Australia, Canada, France, Japan, the
UK, and the USA [16]. All data available in the 20th
century for AC and for pneumonia and influenza (P&I)
monthly mortality by age group were used. Wherever
possible, 5-year age grouping was used, and all datasets
end on 31 December 1999. AC mortality records began
on 1 January 1950 for Canada, 1 January 1951 for Japan,
1 January 1959 for the USA and the UK, and 1 January
1968 for Australia and France. The P&I datasets began
on 1 January 1950 for Canada, 1 January 1959 for the
USA and the UK, 1 January 1968 for Australia and
France, and 1 January 1972 for Japan. The age-grouping
practice was modified to allow the use of the data on
some younger age groups in some of the countries with
smaller populations. The Japanese data have not been
used previously in any published analysis.
Influenza-attributable mortality rates (deaths per 1,000
of the relevant population or subpopulation) were esti-
mated using a digital filter technique, which produces
estimates very highly correlated with those of other
methods [17]. This method was selected because it pro-
duces estimates that are strictly additive by age group,
and are consistent in the sense that they are indepen-
dent of which seasons are included in the analytical
sample (For proofs of these assertions, see Additional
file 1. Excel templates for digital filtering of monthly
mortality data are available by request from the corre-
sponding author). For each influenza season and coun-
try, we fitted a simple exponential model to the
estimated excess mortality rate for each available age
Reichert et al. BMC Medicine 2012, 10:162
http://www.biomedcentral.com/1741-7015/10/162
Page 4 of 15
group [18]. AC excess mortality rates (ACxsMR), were
modeled as ACxsMR = k1 × exp (k2 × age), where k1
and k2 vary with time and country. The coefficients k1
and k2 were compared across epidemic seasons and
countries by means of 95% confidence intervals (for
tabulated results, see Additional file 2).
Mortality rate estimates for the youngest and oldest
age groups differed by two orders of magnitude. To
enable direct comparisons, we transformed the values of
excess mortality for each age group and country using a
standard technique, that of centering and scaling C&S).
(see Additional file 1 for a description, references, and a
table of scaling parameters by country.) C&S standar-
dized excess mortality rates for every age group have a
mean of zero and a standard deviation of one. The value
associated with each season is the number of standard
deviations by which that season’s mortality rate differed
from the mean for that age group/country. C&S excess
mortality rates for all age groups and countries can be
plotted on the same graph. We used two graphical
forms. For each country, we plotted these rates versus
time in a ‘rainbow’ coloration for age groups, with the
oldest age group in dashed black for easy identification
(see Additional file 1, Figure S1). We also generated an
‘area’ form of each rainbow plot in which the area
between a peak or trough and zero ordinate was filled
with color.
Past pandemics have varied widely in their mortality
rates. We sought insight into the two components of
age-specific mortality rates attributable to influenza: the
attack rate and the case fatality rate. We began with a
recent discussion of attack rates for three pandemics
[19]. Following the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) state-
ment guidelines (which aims to help authors improve
the reporting of systematic reviews and meta-analyses)
[20], we used the Web of Science search engine with
the following keyword string for the title field: ‘influenza’
AND ‘1918’, for articles relating to the 1918 pandemic;
‘influenza’ AND ‘1957’ for articles relating to the 1957
pandemic; ‘influenza’ AND ‘1968’ for articles relating to
the 1968 pandemic; and ‘influenza’ AND ‘2009’ for arti-
cles relating to the 2009 pandemic. We filtered out arti-
cles that did not include data on pandemic influenza
incidence rates according to age groups. For additional
relevant articles, we also examined articles cited in the
references of the filtered articles.
Results
The A(H2N2) pandemic
We prepared semi-logarithmic plots of excess AC mor-
tality rates for the seasons before and after the A(H2N2)
pandemic in Canada and Japan, respectively (Figures 4A,
B), and fitted trend lines to the data for these seasons.
R2 was greater than 0.99 for all fits to the Japanese data
and for all seasons in Canada except the pandemic sea-
son 1957/8 and the unusual 1961/2 season. P-values for
all H2 era seasons for Canada were less than 10-4 (mean
5 × 10-7) and for Japan less than 5 × 10-9 (mean 5 × 10-
10), therefore an exponential relationship provided an
excellent fit between AC excess mortality rate and age.
The unusually high quality of the fit to the model is also
testimony to the consistency of the estimation process,
as the digital filter was applied to what should be more
or less independent data series.
The excess mortality rate age distribution in the 1955/
6 A(H1N1) pandemic season in Canada is shown in Fig-
ure 4A (solid purple line). In the subsequent pandemic
season, 1957/8, the ACxsMR trend line (red dashed
line) had a markedly lower slope (0.1026 ± 0.0146 versus
0.127; R2 = 0.985). The pandemic line appeared to rotate
clockwise about the age of 80 years with respect to the
trend of the 1955/6 season, demonstrating that mortality
was lower for groups older than around 80 years, and
higher for younger groups. In fact, pandemic mortality
for the three highest age groups was lower in the pan-
demic season than at any time in the subsequent decade
(Figure 4C). Relative to the pandemic season, mortality
declined for the 1958/9 season (blue line) only for the
youngest two age groups; and was sharply higher for all
people aged over 65 years, being up to 40% higher for
the oldest age group. R2 was again greater than 0.99,
suggesting that the pure exponential relationship, dis-
rupted in the pandemic, had been reasserted. Through-
out the H2 era, the excess mortality rates for the oldest
three age groups did not vary by more than 10% and
did not show any systematic tendency, whereas younger
age groups exhibited serial reductions of more than 40%.
There were several differences in the H2 pandemic in
Japan. First, the mortality in the preceding H1 season
was generally greater than that in the pandemic. Expo-
nential fits were excellent (R2 > 0.99) for every season.
The ‘axis of rotation’ appeared to be about the age of 45
years, that is, mortality was lower in 1957/8 than in
1956/7 for every age group of 45 years and older, and
the difference increased with age, from approximately
20% for the youngest of these age groups to approxi-
mately 50% for the oldest (Figure 4B). The 1958/9,
1962/3, 1964/5 and 1967/8 H2 seasons were a progres-
sion of increases in exponential slope, with each incre-
ment in the slope trend being statistically significant (for
tables of coefficients and uncertainties, see Additional
file 2: XS mortality rates fitted to an exponential model)
The reductions in mortality for the youngest age groups
were preserved in and after 1964/5, but mortality
increased proportionately in all groups aged over 55
years, increasing by over 30% during the 1967/8 season
for the oldest elderly group. The 1961/2 season was
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divergent. We have no information on the dominant
virus in circulation for that season in Japan, and so can
only note that the age variation is strikingly similar to
that in the last H1-dominated season (1956/7), and dis-
similar to all other H2 seasons (Figure 4B).
The pandemic reduction in mortality in the old elderly
thus lasted only one season in Canada, but extended
over seven seasons in Japan. The age variation in excess
mortality rate showed no tendency to deviate from a
highly significant exponential relationship in Japan in
any season, and the time trend to higher slope (that is,
of increasing relative mortality risk for the increasingly
elderly) was monotonic (Figure 4D).
The A(H3N2) pandemic in Canada and the USA
The emergence of A(H3N2) viruses was very similar in
Canada and the USA, but very different in the rest of
the world. In the USA, (largest P-value, 2 × 10-7, mean
7 × 10-8) mortality among elderly people was relatively
high during the most recent H2 season in the USA, in
1967/8 (Figure 5F, chartreuse line). The pandemic sea-
son trend was rotated clockwise from that for the pre-
ceding season (dark-green dashed line). The slope
change was 0.03 units, and the uncertainty in each esti-
mate was 0.006 units. The 1969/70 seasonal trend was
precisely parallel to that for 1968/9, but at two-thirds of
the amplitude of the earlier season. The mortality in the
next H3 season, 1971/2, was indistinguishable from that
of 1969/70; however, in 1975/6, there was a statistically
significant increase in slope, a counterclockwise rotation,
with younger age groups enjoying a reduction in mortal-
ity of about one-third, while the oldest age groups had a
50% increase in mortality rates.
For the emergence of H3 viruses in Canada, the P-
values for the trends displayed were strikingly higher
(mean 4 × 10-4), with the highest value, 1.8 × 10-3, seen
for the pandemic season 1968/9 (Figure 5b). Although
this highest P-value is still very small, we believe that
the relatively low R2 value of 0.88 for this particular fit
should be taken as corroboration of a visually apparent
departure from exponentiality. The trend lines for 1969/
70 and 1971/2 were again indistinguishable. The mortal-
ity reduction for younger age groups and the 50%
increase in the mortality for the oldest elderly groups
(those aged over 80 years) in 1975/6 were also similar to
those in the USA.
Figure 4 A semi-log plot of excess All-Cause excess mortality rate variation with age for epidemic seasons during the era of
circulation of influenza A(H2N2) viruses in Canada (A) and Japan (B). The pandemic season appears as a dashed red line. Old elderly had
their lowest mortality in that season. The most recent precedent season dominated by H1 viruses appears in purple. Mortality was generally
decreased in the pandemic in Japan. The different time courses of immune escape in these countries are shown in Canada (C) and Japan (D)
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The A(H3N2) pandemic elsewhere than Canada and the
USA
Relative to the most recent season dominated by H2
viruses (chartreuse trend lines), mortality declined in
Australia, Japan, and the UK (Figures 5A, D, E) in the
pandemic season of emergence (long-dashed dark-green
trend lines for 1969, 1968/9 and 1968/9, respectively),
but only in the oldest elderly people (aged over 78
years, approximately). The P-values for these fits
dropped by 10-fold, 25-fold and 2-fold, respectively. For
the second season after emergence (1970, 1969/70,
1969/70), the trend line (fuchsia) slope decreased by an
amount about equal to the uncertainty in the previous
season’s estimate, and the P-value for the fits dropped
another 40-fold, 10-fold, and 10,000-fold (10-10 to 10-6).
This is the statistical result of an increase in mortality
rates for all ages younger than 75 years, and no change
at all for older age groups. Younger age groups experi-
enced progressive reductions in mortality in intervening
H3-dominated seasons (1972, 1973/4, 1972/3), but the
older age groups had no change until later seasons
(1974, 1975/6, 1975/6, when they experienced a 35 to
40% increase in mortality rates. Younger age groups
alone exhibited further adaptation (mortality reductions)
in 1976 in Australia but not in the other two countries.
The H3 pandemic in France was unusual in a different
way (Figure 5C). Unfortunately, age-specific mortality
data were not available for the most recent H2-domi-
nated season. In Australia, Japan and the UK, the overall
increase in mortality from the first to the second pan-
demic season for age groups younger than 75 years was
50 to 70%, whereas in France this increase was four-fold
(400%; compare dashed dark-green with the fuchsia
trend lines), from about half the mortality levels of the
three countries listed above to about the level of the
highest of these (the UK). There was sequential and pro-
portionate adaptation of younger age groups through
the 1975/6 season, but no apparent change in the mor-
tality rates for the oldest age group.
These data are displayed in a different manner for
further clarity (Figure 6A-F). Each panel shows the C&S
excess AC mortality for one of the six countries using
an area coloration scheme, with a dashed black line
marking the oldest age group. All peaks after 1967/8
occurred in seasons dominated by H3 viruses. In the
USA (Figure 6F), the dashed line traced the top or near-
top of every peak except for those for the pandemic of
1968/9 and the following seasonal epidemics, which
were dominated by H3 viruses, until the 1975/6 season.
The dashed line also outlined nearly all troughs. Begin-
ning in the pandemic season and extending until the
1975/6 season, C&S excess AC mortality for the pro-
gressively older population was correspondingly lower,
with the oldest age group experiencing mortality below
the mean (less than zero C&S). The reduced mortality
risk was most dramatically lowered in the progression
for the age group aged 75 to 79 years, and we infer that
all people of age above the mid-point of that age group
(the threshold age) were protected from the pandemic
virus and its immediate descendant viruses. A drift var-
iant emerged in 1975/6, the ‘Victoria’ variant, which
abrogated the immunologic protection of these above-
Figure 5 A semi-log plot of excess all-cause mortality rate variation with age for epidemic seasons before, including and immediately
after the emergence of A(H3N2) viruses in (A) Australia, (B) Canada, (C) France, (D) Japan, the (E)UK and the (F) US, in alphabetical
order. The pandemic season is shown as a dashed dark-green line. For countries other than the USA and Canada, the season of emergence was
one of low mortality, while the second season was severe (short-dashed fuchsia line). The oldest elderly population over the age of 78 years had
reduced mortality in the severe pandemic season, everywhere. This mortality reduction was lost abruptly in the 1975/6 season, except in France.
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threshold elderly people, reinstituting the higher risk of
mortality for influenza to the very elderly person. The
period 1968/9 to 1974/5 was the only interval in the 40-
year data span in which the oldest elderly population
was not at the highest relative level of mortality risk.
The impact of influenza from 1976 to the end of the 20th
century
In four countries (Canada, France, the UK, and the
USA), there was no change in mortality rates for the
oldest three age groups after 1976 (Figure 7B, C, E, F);
the lavender to purple-hued trend lines rose to the same
point at oldest age for the relevant countries). In
Canada, France, and the UK, the trend lines for H3-
dominated seasons after 1976 were not statistically sig-
nificantly different in slope or magnitude from that for
the 1975/6 season. In France, there was no apparent
trend toward changing slope or magnitude. For Canada
and the UK, this possible trend did not reach statistical
significance. For the USA, the trend towards progressive
adaptation of younger age groups, reflected in increasing
slope and decreasing magnitude for seasons after 1975/6
(Figure 7F), became statistically significantly different
from 1975/6 only in 1997/8.
Figure 6 Area plots of centered and scaled excess all-cause mortality for all age groups for all data available for the second half of
the 20th century. Data are for (A) Australia, (B) Canada, (C) France, (D) Japan, (E) the UK, and (F) the US. Values for the oldest age group are
outlined by a black dashed line and filled in purple. Color breakthroughs demarcate seasons of immunoprotection of the old elderly sub-
population.
Figure 7 A semi-log plot of excess all-cause mortality rate variation with age for H3-dominated seasons of immune escape and later.
Six countries ((A) Australia, (B) Canada, (C) France, (D) Japan, (E) the UK, and (F) the USA) are shown, in alphabetical order.
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In Australia (Figure 7A), the trend lines for the three
most severe H3 seasons after 1976 (1982, 1989, and
1997) were significantly different from 1976 in both
slope (steeper) and magnitude (lower); however, they
were not significantly different from one another. In this
case, then, there was a reduction in mortality in all age
groups, slightly greater in younger age groups.
In Japan (Figure 7D), the slopes for later H3 seasons
(1982/3 and 1994/5 or 1997/8) were significantly differ-
ent from one another and from the 1975/6 season, but
the time trend was toward lower slope, suggesting mor-
tality reduction favoring the older elderly population.
Overall, there was a four-fold reduction in the mortality
rates for all age groups, about equally between 1975/6
and 1997/8.
Do pandemic attack rate data provide additional insight
into immunoprotection?
The entire human population is potentially susceptible
to pandemic viruses except for those individuals who
are relatively immune as a result of previous exposure
to similar viruses in the remote past. If such viruses are
so highly transmissible that the general characteristics of
social contact among individuals are sufficient to largely
determine the age distribution of cases [21] (for exam-
ple, that each age group has primary social contact with
itself), then it is not unreasonable for there to be signifi-
cant similarities in attack rates across pandemics. The
distribution of cases by age in pandemic seasons was
well characterized for the 1918/9 A(H1N1) pandemic
season in the USA [22] and the 2009 pandemic in the
UK [23], but only sparsely for the H2 and H3 pan-
demics, for which detailed data were available only for a
single site for families with school-age children [24] plus
a single nursing-home population for the H3 pandemic
[25] (Figure 8). There is remarkably little scatter in the
data for 1918/9, 1957/8, the nursing-home population
from 1968/9, and the 2009 influenza pandemics. How-
ever, the data of Davis et al. [24] for 1968/9 were essen-
tially flat versus age, and were different not only from
those of all other pandemics, but also from the data on
older people in a more isolated environment in the
same pandemic. Ignoring data for children aged younger
than 7 years (for whom the age trend is likely to be
positive), the data are fit well by a linear model of nega-
tive slope. R2 for the fit to all the data except the 1968
data of Davis et al. is 0.81 (approximately P = 10-12).
The data presently do not permit a definitive statement.
A pan-pandemic trend, if validated, would greatly sim-
plify future modeling studies. Further study would be
valuable because: 1) preparations for every pandemic
should then be similar, focused on interrupting conta-
gion, and concentrated on younger age groups; and 2)
because pandemic viruses then differ only in their
mortality impact (case fatality rates), it becomes interest-
ing to ask whether these differences are qualitative or
quantitative.
Discussion
In this study, we characterized the data for eight pan-
demic seasons in six economically developed countries:
two countries for the A(H2N2) pandemic and all six for
the A(H3N2) pandemic. In all these, an older subpopu-
lation of the elderly population experienced reduced
mortality in the year of emergence. In countries other
than Canada and the USA, mortality was unchanged
from the preceding H2 season for all younger age
groups in the season of emergence of the H3 viruses,
but strongly increased in the second season after emer-
gence, Mortality remained unchanged, however, in the
oldest elderly population. It is clear, therefore, that the
primary element affecting overall mortality in pandemic
emergence is the existence of a relatively immune sub-
population aged above a threshold age. As a result, pan-
demic mortality was relatively greater in younger age
groups in the first season, and absolutely increased over
the H2 baseline in the second season, except in Canada
and the USA, where these effects could not be sepa-
rated. We therefore suggest that there is no pandemic
‘shift’ in mortality to younger age groups, merely a viru-
lence-directed change in overall mortality, modified
from a purely exponential variation with age by the rela-
tive immunity of persons above a threshold age who
had experienced infection in the past with a virus simi-
lar to the emerging virus. This mortality sparing was
eventually lost in every country. In Australia, Canada (in
both the H2 and H3 pandemics), Japan (in the H3 pan-
demic), the UK, and the USA, mortality increased shar-
ply in the spared age groups in a single season. We call
this step up in mortality in previously protected subpo-
pulations ‘immune escape,’ in epidemiological analogy to
the term that was first used to characterize the escape
of spontaneously metastasizing tumors from immunolo-
gical control [26], and was later applied to a discussion
of impaired immunological response of T-cells in infec-
tious disease [27]. In France, younger age groups pro-
gressively gained mortality reductions until 1975/6, after
which time there were no additional gains for any age
group. In the H2 pandemic in Japan, all age groups had
reduced mortality in the pandemic season, but the pro-
tection was proportionately larger with age. This protec-
tion was lost sequentially, season by H2 season.
The A(H2N2) pandemic
The only two countries for which age-specific mortality
data were available for both the H3 and H2 pandemics
were Canada and Japan. In both countries, pre-pan-
demic epidemic seasons were well characterized by
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highly statistically significant, log-linear, positive slope
trends with increasing age for excess AC mortality (Fig-
ure 4A, B). The pandemic seasons were characterized by
overall levels of mortality that were discontinuous with
the trends for previous seasonal epidemic years. The
pandemic mortality rates were higher or lower than
those for previous years, depending on the relative viru-
lence of the emerging virus. In Japan, the H1 season
immediately prior to the H2 pandemic was particularly
severe. Accordingly, in the pandemic year, every age
group experienced a decline in mortality, and this differ-
ence increased monotonically with age. Subsequently,
post-pandemic mortality rates moved monotonically
back toward the trend in pre-pandemic seasons, while
maintaining a highly significant exponential relationship
The A(H3N2) pandemic
The A(H3N2) pandemic was remarkable in that the year
of emergence was a season of reduced mortality every-
where in the world except in Canada and the USA,
while the second season was severe everywhere. The
first season of circulation of A(H3N2) viruses produced
severe mortality in Canada and in the USA, taken in its
entirety, but mortality was relatively low, not only in
most other countries, but also in the Pacific provinces
of Canada, the central and mountain regions of the
USA, and in Mexico [28]. The basis for this variability is
controversial [29,30]. In Japan and the UK, there was a
one-year delay (Figure 5D, E), after which the situation
played out in essentially the same way as in northern
North America. Similarly, in Australia, the first pan-
demic season was 1969, but severe mortality did not
occur until 1970, followed by immune escape in 1974
(Figure 5a). In France (Figure 5c), the first H3 season
was also relatively mild; however, the 1969/70 season
was extraordinarily severe. Immune escape apparently
did not occur in France; rather, there were progressive
mortality reductions in younger age groups, with no
change in the oldest elderly mortality rates even to the
end of the century. This implies that the circulation of
H3 viruses was different in France from that in the
neighboring UK, possibly in the 1970s, but certainly
during the late 19th century when H3-like viruses
circulated.
Figure 8 An estimate of age-specific attack rates hypothetically applicable to all pandemic seasons. The data displayed are for the
pandemics of 1918/9, 1957/8, 1968/9. and 2009/10. The data for 1968/9 come from two studies. The data from Davis et al. were fit separately.
All other data are fit well by a linear trend that decreased linearly with age.
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The initial reassortment event that gave rise to the
1968 pandemic A(H3N2) strain apparently resulted in a
mismatch between the avian H3 hemagluttinin and the
humanized N2 neuraminidase. The H3 viruses that cir-
culated in the late 1800s had equine-like versions of N2
[31,32]. However, the differences in severity in the first
H3-dominated seasons in locations other than Canada
and the USA probably reflect not only different rates of
resolution of functional mismatch of these two gene
products [33], but also a sifting of the large number of
genomic combinations that were identified in circulation
beginning in 1969, owing to an intermixing of the two
clades that had emerged in the most recent years of cir-
culation of H2 viruses [34]. The lack of a single course
of evolution is especially evident in the schema for the
PB2 and PA genes [4]. In other words, it is the refine-
ment in the field of the performance of a large number
of permutations that were generated as H3 replaced H2
in many recombination events, rather than a single
genomic substitution, that best explains the sputtering
entry of H3 viruses in most parts of the world.
Comparison of the H2 and H3 pandemics
The mortality patterns of the H2 and H3 pandemics
were similar in Canada, with steps up in mortality and a
sharp demarcation in age above which immunoprotec-
tion was evident. The post-pandemic escape from
immunoprotection was also a step in time. The greater
mortality attributed to the earlier pandemic was due to
the more complete immunoprotection in the H3 pan-
demic [35]. The pandemic mortality reduction in the H2
pandemic in Japan increased directly with age. The dif-
ferent levels of immunoprotection, recycling ages, and
pattern of immune escape in Canada and Japan suggest
that there were significant differences between the H2
viruses of the 19th and 20th centuries [36], and that the
circulation of these only somewhat similar viruses in the
late 1800s produced local variants that were also very
different. It may be relevant that Japan was somewhat
isolated before its opening to outsiders in the late 1800s.
Conclusions
Pandemics do not ‘shift’ mortality to younger ages
From this study, it is evident that pandemics do not
‘shift’ mortality to younger ages. Rather, the entire mor-
tality level is simply reset to the virulence level of the
emergent virus. This reset is accompanied by immuno-
protection in older age groups, which is determined by
their level of previous experience with viruses similar to
that emerging.
All known pandemics have involved ‘recycled’ viruses
It is well accepted that older persons (aged over 45 to
55 years of age) were spared in the 1918 A(H1N1)
pandemic [37,38], although as reported above for H2
viruses, recent data from central Mexico and Colombia
suggest geographic differences in pre-existing immunity
to these viruses [39,40]. We and others have shown that
older people (aged over 62 years), were spared in the
2009 H1N1 pandemic [10] and individuals older than 26
years were reported to be spared in the mini-pandemic
re-emergence of H1N1 viruses in 1977/8 [14]. There-
fore, it appears that in all five events over the past 100
years in which an influenza virus emerged with pan-
demic effect, a significant proportion of then-living indi-
viduals aged above a particular threshold age were
immunologically protected from the emergent virus.
Such viruses are said to be ‘recycled’ [25]. Our data are
consistent with sero-archeology studies in which antibo-
dies to pandemic viruses have been identified in age-
cohort sera drawn before the H3 pandemic [41]. Unfor-
tunately, the sero-archeology data on past circulation of
H2 viruses is inconsistent. As we noted above, the 2009
pandemic virus was most similar to H1 viruses that cir-
culated before 1947. Therefore, the concept of recycling
must be broadened to include not only pandemic
viruses, but also antigenically significant variants of
emergent viruses. Lessler et al. [42] have recently shown
that sero-archeology curves (plots of antibody levels in
age cohorts versus the cohort age) of pandemic viruses
and their variants are essentially indistinguishable,
except for a displacement in time to the date of emer-
gence of the variant.
Immunoprotection from recycled viruses is a cardinal
attribute of pandemics
It is clear that immunoprotection from recycled viruses
is a cardinal attribute of pandemics, and this conclusion
leads logically to several corollaries, as follows.
Immunoprotection should direct pandemic planning
Vaccines will not be required for protection for those
aged above the age of recycling (Above the Age of
Recycling Persons; AARPs), for both pandemic seasons
and epidemic seasons dominated thereafter by variants
of the pandemic virus, until immune escape occurs.
Therefore, this otherwise high-risk population segment,
easily defined in advance for any candidate pandemic
virus, can be provisionally removed from pandemic
vaccine planning. As there is a consensus among those
modeling vaccine performance that deploying vaccine
first to children and working adults should provide
more effective protection, and as global vaccine pro-
duction is inadequate, this should improve the level of
effective coverage. Of course, if an AARP should
become infected with pandemic influenza, the high a
priori expected case fatality rate implies that antiviral
resources should be made immediately available to
them.
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Immunoprotection does not prevent infection, only the
consequences of infection
We have remarked that the data on variation in pan-
demic attack rate with age appears surprisingly similar
across all four pandemics, suggesting a linear decline
with age. We found similar threshold ages above which
immunoprotection from mortality was present in both
the H2 and H3 pandemics. However, these thresholds
are both higher than the age threshold for protection in
the 2009 H1 pandemic (approximately 62 years), the
1918 H1 pandemic (45 to 55 years) and the 1977 mini-
pandemic (approximately 26 years). If a universal attack
rate for pandemics is a viable hypothesis, then this must
mean that immunoprotection from mortality does not
influence the infection rate, but only the severity of its
consequences. It could even be argued that a universal
pandemic attack rate is the epidemiologic correlate of
the well-known immunologic observation that the con-
trol of the spread of virus infections lies in the rapid
response of memory B- and T-cells, but that circulating
levels of antibodies and armed T-cells are insufficient to
prevent viral entry entirely [43,44].
Immunoprotection must be explicitly considered in vaccine
trials
Trials of vaccines and studies that analyze the effects of
influenza vaccination should either exclude or analyze
as positive controls the already immune AARP popula-
tion segment, both for the pandemic season and for the
following seasons until immune escape occurs. After
immune escape occurs, and until a future time when
descendant viruses have mutated so completely that
infection no longer stimulates the pattern of response
conditioned by exposure at an early age to similar
viruses (that is, original antigenic sin, OAS [45]), AARPs
will falsely appear to be vaccine failures. The degree of
vaccine effectiveness will necessarily be very low, possi-
bly even negative in the first season of immune escape,
and will rise as the evolutionary distance from the pan-
demic virus increases [46]. Unfortunately, little is known
about the restoration to immunological grace after OAS.
Immunoprotection may be a key to pandemic survival for
organizations too
If pandemic attack rates are indeed universally low for
the pre-immune elderly person, employers should con-
sider prospectively recruiting AARPs for positions cru-
cial to the missions of their enterprises. AARPs
experience seasons of emergence as no more severe
than seasonal influenza epidemics. Absenteeism among
working-age populations in severe pandemics could
reach levels of 50% or more. Assembly line-like activities
can usually tolerate no more than 20% absenteeism. It is
true that the mortality rate of AARPs is likely to be
absolutely higher than that of the younger population in
pandemics; but it will be relatively lower, and the attack
rate for AARP’s will be absolutely lower.
Immune escape may be accompanied by substantial
increases in mortality and morbidity
Our data show that immune escape may be immediate
or delayed for several seasons. This may also be seen in
reports analyzing the 1918 pandemic, from which
immune escape, as an increase in excess mortality
among the elderly population, did not occur until 1926
[47,48]. There is some genomic insight into the evolu-
tion of H3 strains, A series of amino acid changes
occurred between 1971 and 1975 [49]. Coincident with
the loss of immunoprotection in AARPs in 1975/6, the
variant A/Victoria/3/75 appeared, in which two glycosy-
lation sites were added onto the globular head of HA, at
positions on HA 81 and 126, while losing a site at posi-
tion 63. These nascent glycosylation sites were located
within antigenic sites E and A, respectively, and the site
that was lost at position 63 was also within antigenic
site E. We hypothesize that this change in glycosylation,
particularly the addition of the position 126 site within
antigenic site A, abrogated the immunoprotection of the
OAS response in AARPs, allowing re-infection [50].
Lessler et al. [42] found that H3/Victoria/3/75 was the
least antigenic of the nine H3 viruses in their study, all
of which circulated sequentially. This is surprising given
the large excess mortality rate estimated for the 1975/6
season. Two studies have reported that vaccination of
humans with inactivated viruses does not produce an
OAS effect, that is, induced antibody shows a higher
affinity to a previously encountered influenza virus
strain than to the virus strain present in the vaccine
[51,52]. However, it may be of significance that the OAS
strain in the first of these studies was Victoria/3/75.
Kim et al. [53] found that sequential administration of
inactivated virus vaccine resulted in a higher viral load
and defective clearance in mice on challenge with the
second virus in the sequence, and they also found (again
in mice) a large OAS effect on serial natural infection,
independent of order. Possibly more importantly, Zhou
and Deems [54] have argued that, in dengue (for which
there are four known viral subtypes), OAS is augmented
when infection with a highly antigenic subtype is fol-
lowed by infection with a cross-reactive subtype that is
significantly sub-dominant to the first, and is muted in
the reverse situation (first infection by a sub-dominant
subtype followed by second infection with a more domi-
nant subtype). This would appear to be the situation
that existed in 1975/6 with the emergence of the Vic-
toria/3/75 variant. Zhou and Deems provide a mathema-
tical model of T-cell response that seems to account
generally for the observed response. If an analogy may
indeed be extended to influenza, managing the T-cell
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response is an important feature currently lacking in
influenza vaccines that needs to be addressed if immune
escape is to be mitigated.
If an emergent virus is, like novel H1N1 of 2009, a
virus recycled from a point well along in its adaptation
to the human species, antigenic sites will have drifted in
both amino acid sequence and in the generation of gly-
cosylation sites. Because the 2009 virus is relatively non-
virulent, the analogy with dengue would suggest that the
potential for an augmented OAS response accompany-
ing immune escape for this virus is relatively low. SOIV
2009 offers a rich opportunity for the study of immune
escape, because many of the mutation pathways poten-
tially open to this virus are precluded by the continued
circulation of H1N1 viruses that re-emerged in 1977.
With a relatively low recycling age (> 62 years) the
number of susceptible people, initially low, is now
further reduced. Evolutionary pressure on this virus
must be enormous, thus rapid change or extinction
should be anticipated.
The mortality rate attributable to influenza was diminished
after 1976, but not as a result of vaccination
Over the second half of the 20th century, Canada and
the USA had, by far, the lowest influenza-mortality rate,
about half that of the highest rate in these countries,
which was in the UK. However, a common feature of
our graphs (Figure 6; see Additional file 1, Figure S1) is
that after 1975/6, only a few mortality peaks anywhere
exceeded the mean excess mortality (C&S = 0). Com-
pared with the mean excess mortality in the 25 years
before 1980, excess mortality for the period 1980 to
2000 was 40% lower in Japan, about 20% lower in Aus-
tralia and the UK, 10% lower in France, and 5% lower in
Canada and the USA. Both mortality and variation came
to be highest in the UK, among these six countries.
There was no discernible trend in influenza-related
mortality in four of the six study countries after 1976
(Canada, France, the UK. and the USA). In Australia,
mortality rate models of H3 seasons after 1976 differed
significantly, showing mortality reduction in all age
groups, but proportionately less in the older elderly
population. Only in Japan, where curiously, the elderly
population was not vaccinated at all, was there evidence
of mortality reduction favoring the older elderly popula-
tion. For the peak mortality years (all H3 seasons), the
oldest elderly population in all countries had the highest
relative mortality (Figure 6, dashed lines). By contrast, in
type B and A(H1N1)-dominated seasons (the troughs),
the oldest elderly population tended to have either the
lowest relative mortality, or had values that were little
different from those of younger people. These observa-
tions are remarkable because programs for influenza
vaccination principally targeting the elderly population
were instituted in all of these countries except for Japan,
and these programs dramatically increased in coverage
after 1980. In Japan, influenza vaccination targeted only
children in a program that was begun in 1972 and that
terminated in 1987 [55]. None of the elderly population
received any vaccine, and no influenza vaccine was
deployed in Japan during the period 1993 to 1996/97,
after which a more conventional vaccination program
including elderly people was deployed.
Could influenza vaccine be more effective in B-domi-
nated and H1N1-dominated seasons than in those
dominated by H3 viruses? This would run counter to
the conventional wisdom that inactivated influenza vac-
cines induce lower rates of seroprotection against B
viruses than against either H3N2 or H1N1 viruses [56].
The lethality of H3 viruses and the benign nature of B-
type and H1N1 viruses for the elderly person is possibly
better explained by the relatively low mutation rate of
B-type influenza viruses and greater historical experi-
ence with viruses similar to the H1 viruses. In any case,
it is clear that the pattern of influenza-attributable mor-
tality, including the overall decline, has been unaffected,
at the population level, by the distribution of influenza
vaccine.
If there is no evidence that excess mortality has
declined in the older elderly population, who have been
subject to the greatest increase in and the most compre-
hensive coverage with influenza vaccination; if the only
decrease in excess mortality among the older elderly
occurred in the one country that did not vaccinate its
elderly population; and if an argument can be made that
conventional, inactivated virus vaccines may even engen-
der a defect in viral clearance, then the trial design for
vaccines should be re-examined. One of several poten-
tial issues these observations raise is the use of placebo
controls. The well-characterized lack of efficacy in the
elderly population [57-59] suggests that ethical concerns
about placebo use may be misplaced. Detection of vac-
cine effects is intrinsically difficult. Detection of such
effects in a population with little expected effect requires
large samples and control of all anticipated confounders.
We suggest that investigation of influenza vaccines in
elderly populations might be best performed using as
many such controls as possible. Additionally, if recent
progress in understanding the immunology of the den-
gue virus has a valid analogy or indeed any application
to influenza, then the immune escape of AARPs is
potentially fraught with particular peril, because pan-
demic viruses are often highly immunodominant,
whereas subsequent variants are less so. It is likely that
new forms of influenza vaccine [60] and possibly new
modes of administration may be needed to protect
those elderly people who were initially immune, from
the effects of exposure to variants of emergent viruses at
and after immune escape.
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Additional material
Additional file 1: Exposition of Methods and Models. Details of
techniques used are presented, together with formal proofs of the
claimed properties of the method for estimating excess mortality. This
file also includes a rainbow coloration version of the text Figure 6 to
permit the reader to estimate the actual data used.
Additional file 2: XS mortality rates fitted to an exponential model.
This Microsoft Excel file contains estimates for the coefficients of an
exponential fit to every season for which data were available for each of
the six countries studied.
Abbreviations
AARP: Above the age of recycling persons; AC: All-cause (used for both
mortality due to all causes and excess mortality due to all causes); ACxsMR:
All-cause excess mortality rate; B-type: Influenza subtype B; C&S: Centering
and scaling; H1, H1N1: Influenza subtype A(H1N1); H2, H2N2: influenza
subtype A(H2N2); H3, H3N2: Influenza subtype A(H3N2); N2: Influenza type A
(neuraminidase type 2); OAS: Original antigenic sin.
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